Edward E. Kadel

11.1k total citations · 1 hit paper
37 papers, 810 citations indexed

About

Edward E. Kadel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Edward E. Kadel has authored 37 papers receiving a total of 810 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 13 papers in Surgery. Recurrent topics in Edward E. Kadel's work include Cancer Immunotherapy and Biomarkers (23 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Prostate Cancer Treatment and Research (10 papers). Edward E. Kadel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Bladder and Urothelial Cancer Treatments (13 papers) and Prostate Cancer Treatment and Research (10 papers). Edward E. Kadel collaborates with scholars based in United States, United Kingdom and France. Edward E. Kadel's co-authors include Sanjeev Mariathasan, Thomas Powles, Kobe Yuen, Charles G. Drake, Patrick Williams, Silke Gillessen, Christopher J. Sweeney, Jennifer Doss, Gary L. Buchschacher and Karim Fizazi and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Edward E. Kadel

35 papers receiving 790 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

2022 157 citations Thomas Powles, Kobe Yuen et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward E. Kadel United States	14	479	313	286	180	113	37	810
Josue Samayoa United States	10	414 0.9×	198 0.6×	232 0.8×	266 1.5×	137 1.2×	17	671
Ariella Sasson United States	9	632 1.3×	250 0.8×	208 0.7×	267 1.5×	210 1.9×	16	967
Zhi L. Teo Australia	13	718 1.5×	214 0.7×	470 1.6×	415 2.3×	275 2.4×	18	1.2k
Anshuman Panda United States	10	424 0.9×	211 0.7×	215 0.8×	358 2.0×	215 1.9×	24	844
Kimberly M. Komatsubara United States	15	370 0.8×	198 0.6×	184 0.6×	309 1.7×	131 1.2×	25	810
Samir Tawadros Germany	16	225 0.5×	81 0.3×	352 1.2×	254 1.4×	69 0.6×	34	863
Huqun Japan	10	469 1.0×	578 1.8×	123 0.4×	343 1.9×	262 2.3×	12	992
Hallie Wimberly United States	12	1.0k 2.1×	319 1.0×	394 1.4×	391 2.2×	328 2.9×	19	1.5k
Kaiming Sun United States	9	685 1.4×	105 0.3×	268 0.9×	448 2.5×	78 0.7×	20	1.1k
Nicole Provost United States	9	455 0.9×	309 1.0×	508 1.8×	269 1.5×	84 0.7×	10	986

Countries citing papers authored by Edward E. Kadel

Since Specialization

Citations

This map shows the geographic impact of Edward E. Kadel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward E. Kadel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward E. Kadel more than expected).

Fields of papers citing papers by Edward E. Kadel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward E. Kadel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward E. Kadel. The network helps show where Edward E. Kadel may publish in the future.

Co-authorship network of co-authors of Edward E. Kadel

This figure shows the co-authorship network connecting the top 25 collaborators of Edward E. Kadel. A scholar is included among the top collaborators of Edward E. Kadel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward E. Kadel. Edward E. Kadel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rakheja, Dinesh, et al.. (2025). Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial. Nature Communications. 16(1). 2610–2610. 11 indexed citations

Gupta, Shilpa, et al.. (2024). Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology. 8(8). e2300562–e2300562. 3 indexed citations

Furuya, Hideki, Kaoru Murakami, Ian Pagano, et al.. (2023). Abstract 5456: Application of a multiplex urinalysis test for predicting treatment response in patients with BCG unresponsive bladder cancer: a pilot study. Cancer Research. 83(7_Supplement). 5456–5456. 1 indexed citations

Szabados, Bernadett, Mariano Ponz‐Sarvisé, Edward E. Kadel, et al.. (2022). Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI). Clinical Cancer Research. 28(18). 4083–4091. 3 indexed citations

Powles, Thomas, Kobe Yuen, Silke Gillessen, et al.. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine. 28(1). 144–153. 157 indexed citations breakdown →

Petrylak, Daniel P., Yohann Loriot, David R. Shaffer, et al.. (2021). Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research. 27(12). 3360–3369. 54 indexed citations

Fong, Lawrence, Michael J. Morris, Oliver Sartor, et al.. (2021). A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(17). 4746–4756. 33 indexed citations

Wagle, Marie-Claire, Joseph Castillo, Shrividhya Srinivasan, et al.. (2020). Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer. Cancer Immunology Research. 8(7). 844–850. 6 indexed citations

Chen, Jieming, Shravan Madireddi, Deepti R. Nagarkar, et al.. (2020). In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales. Briefings in Bioinformatics. 22(3). 15 indexed citations

10.

Galsky, Matt D., Romain Banchereau, Habib Hamidi, et al.. (2020). Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.. Journal of Clinical Oncology. 38(15_suppl). 5011–5011. 20 indexed citations

11.

Sweeney, Christopher J., Silke Gillessen, Dana E. Rathkopf, et al.. (2020). Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 80(16_Supplement). CT014–CT014. 47 indexed citations

12.

Yuen, Kobe, Congfen Li, Deepali Rishipathak, et al.. (2019). Abstract 2676: Associations of peripheral biomarkers to outcomes to anti-PD-L1 immune checkpoint blockade in metastatic urothelial cancer. 2676–2676. 1 indexed citations

13.

Williams, Jacqueline P., Marcin Kowanetz, Hartmut Koeppen, et al.. (2016). The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA. Annals of Oncology. 27. vi405–vi405. 1 indexed citations

14.

Powles, Thomas, Dorothee Nickles, Eliezer M. Van Allen, et al.. (2015). Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal for ImmunoTherapy of Cancer. 3(S2). 11 indexed citations

15.

Schmid, Peter, Marcin Kowanetz, Wei Zou, et al.. (2015). 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes. European Journal of Cancer. 51. S602–S602. 3 indexed citations

16.

Gettinger, Scott, Marcin Kowanetz, Hartmut Koeppen, et al.. (2015). Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.. Journal of Clinical Oncology. 33(15_suppl). 3015–3015. 10 indexed citations

17.

Wong, Harvey, Stephen E. Gould, Nageshwar Budha, et al.. (2013). Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist. Drug Metabolism and Disposition. 41(12). 2104–2113. 42 indexed citations

18.

Kadel, Edward E., Kimberly Walter, Rupal Desai, et al.. (2013). Abstract 4978: Lung cancers regulate the immune suppressor PD-L1 by multiple mechanisms, altering its role in tumor survival.. Cancer Research. 73(8_Supplement). 4978–4978. 1 indexed citations

19.

Cherukuri, Anu, Edward E. Kadel, Cheryl Goldbeck, et al.. (2005). Human Antagonistic Anti-CD40 Antibody, CHIR-12.12, Inhibits CD40-Mediated Survival of Chronic Lymphocytic Leukemia B Cells Leading to Cellular Apoptosis.. Blood. 106(11). 2965–2965. 1 indexed citations

20.

Yauch, Robert L., et al.. (2004). Transcriptional-Based Screens for Pathway-Specific, High-Throughput Target Discovery in Endothelial Cells. SLAS DISCOVERY. 9(8). 704–711. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact